This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why the Earnings Surprise Streak Could Continue for Techne (TECH)
by Zacks Equity Research
Techne (TECH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
Myriad Genetics Announces Study Results Of myRisk Cancer Test
by Zacks Equity Research
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
5 Biotech Stocks to Buy Right Now
by Zachary Stutler
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.
CBM vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
CBM vs. TECH: Which Stock Is the Better Value Option?
Earnings Preview: Techne (TECH) Q3 Earnings Expected to Decline
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
Bio-Techne (TECH) sees increase in revenues across key segments.
Techne (TECH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 6.00% and 2.57%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Techne (TECH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANIK or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ANIK vs. TECH: Which Stock Is the Better Value Option?
New Strong Sell Stocks for November 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Techne (TECH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 1.03% and 0.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Q1 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Techne Partners Micropoint Bioscience, Expands in China
by Zacks Equity Research
Bio-Techne (TECH) believes that its Chinese collaboration is a strategic fit as it will solidify the integration of microfluidic technology for more apt POC diagnostic tools for precision medicine.
New Strong Sell Stocks for October 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH)
by Zacks Equity Research
Momentum stock investors will love Bio-Techne (TECH) seeing its favorable price performance both in short and long term.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.
Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks
by Tirthankar Chakraborty
More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.
Top Ranked Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
Is a Surprise Coming for Bio-Techne (TECH) This Earnings Season?
by Zacks Equity Research
Bio-Techne (TECH) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Bio-Techne's New Simple Plex Cartridge Boosts Protein Segment
by Zacks Equity Research
Bio-Techne (TECH) introduces a multi-analyte cartridge format for the Ella immunoassay platform. The cartridge provides more accurate results at a lower cost.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex Corp (LMNX) is focusing on augmenting its portfolio strength through new FDA approvals.
Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.